Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial-
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: EMONO, Medical air.
- Who it may be relevant to
- Registry conditions: Depression, Neurocognitive Disorders. Basic parameters: from 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial
Overview
Depression in neurocognitive disorders (Alzheimers' disease and related disoders) is a highly prevalent condition, especially in nursing homes. While it is associated with significant distress, the current conventional antidepressants have shown only modest efficacy and exposed to potentially severe side effects. Recent evidence suggests that nitrous oxide (N2O) in its most commonly used packaging of EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide) has rapid antidepressant properties and a good safety profile. However, no study has investigating the antidepressant effect of EMONO in a population of depressed older adults with moderate to severe neurocognitive disorders in nursing homes. The principal goal of the PROTO-EHPAD study is to compare the changes in depressive symptoms in such individuals in a randomized controlled trial with a follow up period of 8 weeks, with a dosage escalation procedure.
Detailed description
Participants will be exposed to 3 sessions of EMONO (or Medical Air), with intervals of 1 week between sessions : a first session of 20 minutes, a second of 40 minutes one week later and a final session of 60 minutes one week later. Efficacy will be assessed 1 week after each session and 4 weeks after the last session.
Interventions
- Drug EMONO
Exposure of Emono via facial mask - Drug Medical air
exposure to Medical Air
Primary outcome measures
- Changes in the CORNELL depression severitý scale between S4 (one week after the last administration of MEOPA or medical air) and S1 (baseline). [Time frame: baseline, week 4]
Secondary outcome measures (4)
- CORNELL scale and GDS scale at weeks 1, 2, 3, 4 and 8 [Time frame: baseline, weeks 1, 2, 3, 4 and 8]
- CGI-S and CGI-I scales at weeks 1, 2, 3, 4 and 8 [Time frame: baseline, weeks 1, 2, 3, 4 and 8]
- The measurement of well-being by the EVIBE visual analogue scale at weeks 1, 2, 3, 4, and 8 [Time frame: baseline, weeks 1, 2, 3, 4 and 8]
- Collection of adverse events at all study visits [Time frame: baseline, weeks 1, 2, 3, 4 and 8]
Eligibility criteria
Inclusion criteria
- Men and women aged 60 and over living in nursing home
- Diagnosis of major neurocognitive disorder according to DSM-V for at least 6 month
- MMSE <= 20/30
- NPI depression >= 4/12
- Patient, family and legal representive consent where applicable Person affiliated to a social security schem
Exclusion criteria
- NPI agitation > 6/12
- Unstable somatic pathology (in particular unstable neurological or cardiological pathologies at risk of interfering with the diffusion of MEOPA) and any unexplained recent neurological abnormality.
- Contraindications to the use of MEOPA
- Patients who have already been treated with MEOPA in the 6 months prior to inclusion, for example for painful treatment
- Sub-physiological plasma vitamin B12 or B9 concentration (below the lower limit of the laboratory value).
- A person participating in a clinical drug study or in a period of exclusion from any clinical study due to previous participation
- Personne participant à une étude clinique médicamenteuse ou en période d'exclusion de toute étude clinique du fait d'une précédente participation
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06382389 · DR220204 · 2023-504691-18-00